Literature DB >> 31288094

Regulatory sanctions for ethically relevant GCP violations.

Rosemarie de la Cruz Bernabe1, Ghislaine J M W van Thiel2, Nancy S Breekveldt3, Christine C Gispen3, Johannes J M van Delden2.   

Abstract

Although EU inspectors and clinical assessors are mandated to identify and act upon ethical issues, regulators lack guidance on how this can be done. Hence, we propose a four-step regulatory approach on ethically relevant GCP violation findings. The first step is identification of the ethical issue. Next is analysis [i.e., identifying the gravity (intensity or severity) and the magnitude (amount and duration) of the ethics violation as well as the responsible person(s) or entity or entities]. The third step is evaluation, (i.e., the process of deliberating to determine the significance of the ethics violation, with the intention of identifying the most reasonable sanction and/or corrective or reparative action). Last is decision-making or the process of choosing and implementing a regulatory course of action.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31288094     DOI: 10.1016/j.drudis.2019.07.001

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  1 in total

1.  Ethics and the marketing authorization of pharmaceuticals: what happens to ethical issues discovered post-trial and pre-marketing authorization?

Authors:  Rosemarie D L C Bernabe; Ghislaine J M W van Thiel; Nancy S Breekveldt; Christine C Gispen; Johannes J M van Delden
Journal:  BMC Med Ethics       Date:  2020-10-27       Impact factor: 2.652

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.